Cardiovascular Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Duke University Medical Center
First-in-class compound proves safe, tolerable in preventing blood clots
March 30th, 2009
A new drug derived from magnolia trees appears to be able to uncouple two important functions of thrombin in blood clot formation and may offer a way to better control the potentially dangerous complications of bleeding and clot formation during procedures to open blocked coronary arteries, say researchers at the Duke Clinical Research Institute (DCRI). Results of the Phase II study of the drug, known as SCH 530348, appear online in the journal The Lancet and will appear in the publication's Mar. 14 issue. An international, Phase III study is already under way. Thrombin is a protein in the blood that performs two key functions in clot formation: It...
Source: Cardiovascular Week (2009-03-30)
|
